🚨 $PLRX
Raben David (Chief Medical Officer) reported special transactions (Non-P/S).
Raben David (Chief Medical Officer) reported special transactions (Non-P/S).
SEC Filing: PLRX
Click to view the official SEC document.
www.sec.gov
October 2, 2026 at 9:30 PM
🚨 $PLRX
Raben David (Chief Medical Officer) reported special transactions (Non-P/S).
Raben David (Chief Medical Officer) reported special transactions (Non-P/S).
🚨 $PLRX
Raben David (Chief Medical Officer) filed Form 3 reporting no initial stock ownership.
Raben David (Chief Medical Officer) filed Form 3 reporting no initial stock ownership.
SEC Filing: PLRX
Click to view the official SEC document.
www.sec.gov
October 2, 2026 at 9:26 PM
🚨 $PLRX
Raben David (Chief Medical Officer) filed Form 3 reporting no initial stock ownership.
Raben David (Chief Medical Officer) filed Form 3 reporting no initial stock ownership.
Wie toll ist eigentlich Brandi Carlile? Entdeckt dank der wunderbaren @tcvaltin.bsky.social. 💗
Thankful for friendship. And music.
www.youtube.com/watch?v=PLrX...
Thankful for friendship. And music.
www.youtube.com/watch?v=PLrX...
Brandi Carlile - You and Me On the Rock feat. Catherine Carlile (In The Canyon Haze)
YouTube video by Brandi Carlile
www.youtube.com
February 20, 2026 at 5:20 PM
Wie toll ist eigentlich Brandi Carlile? Entdeckt dank der wunderbaren @tcvaltin.bsky.social. 💗
Thankful for friendship. And music.
www.youtube.com/watch?v=PLrX...
Thankful for friendship. And music.
www.youtube.com/watch?v=PLrX...
Breaking News: ( NASDAQ: #PLRX ) How the (PLRX) price action is used to our Advantage
#StockMarket #News
#StockMarket #News
September 21, 2024 at 7:45 PM
Breaking News: ( NASDAQ: #PLRX ) How the (PLRX) price action is used to our Advantage
#StockMarket #News
#StockMarket #News
#PLRX Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
https://www.stocktitan.net/news/PLRX/pliant-therapeutics-presents-data-from-its-bexotegrast-program-at-84s1nb4fot86.html
https://www.stocktitan.net/news/PLRX/pliant-therapeutics-presents-data-from-its-bexotegrast-program-at-84s1nb4fot86.html
November 18, 2024 at 11:00 PM
#PLRX Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
https://www.stocktitan.net/news/PLRX/pliant-therapeutics-presents-data-from-its-bexotegrast-program-at-84s1nb4fot86.html
https://www.stocktitan.net/news/PLRX/pliant-therapeutics-presents-data-from-its-bexotegrast-program-at-84s1nb4fot86.html
In the inflammatory #fibrosis space, $PLRX stopped development of bexotegrast avb6/avb1 inhibitor for the treatment of IPF "due to worsening of IPF and acute IPF exacerbation, respiratory-related hospitalization, and/or all-cause mortality" (27 June 2025). Yikes.
July 6, 2025 at 2:22 PM
In the inflammatory #fibrosis space, $PLRX stopped development of bexotegrast avb6/avb1 inhibitor for the treatment of IPF "due to worsening of IPF and acute IPF exacerbation, respiratory-related hospitalization, and/or all-cause mortality" (27 June 2025). Yikes.
A huge blow to #CureIPF and to what I consider the most mechanistically promising intervention in Pulmonary Fibrosis.
Pliant today announced following a secondary review by an outside panel of the DSMB recommendation, that BEACON-IPF is discontinued.
www.globenewswire.com/news-release...
Pliant today announced following a secondary review by an outside panel of the DSMB recommendation, that BEACON-IPF is discontinued.
www.globenewswire.com/news-release...
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified...
www.globenewswire.com
March 3, 2025 at 4:01 PM
A huge blow to #CureIPF and to what I consider the most mechanistically promising intervention in Pulmonary Fibrosis.
Pliant today announced following a secondary review by an outside panel of the DSMB recommendation, that BEACON-IPF is discontinued.
www.globenewswire.com/news-release...
Pliant today announced following a secondary review by an outside panel of the DSMB recommendation, that BEACON-IPF is discontinued.
www.globenewswire.com/news-release...
it's not from her new album, you can listen to it here!!! www.youtube.com/watch?v=PLrX... but please, I definitely recommend going through brandi's discog she's so emotions to me
Brandi Carlile - You and Me On the Rock feat. Catherine Carlile (In The Canyon Haze)
YouTube video by Brandi Carlile
www.youtube.com
November 2, 2025 at 5:25 AM
it's not from her new album, you can listen to it here!!! www.youtube.com/watch?v=PLrX... but please, I definitely recommend going through brandi's discog she's so emotions to me
Getting Better At Saying No | Sarah Millican
YouTube video by Sarah Millican
www.youtube.com
August 29, 2025 at 11:33 PM
$PLRX paused enrollment and dosing in its Phase 2b BEACON-IPF trial of bexotegrast for idiopathic pulmonary fibrosis following a review by the independent Data Safety Monitoring Board.
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/pl...
$PLRX $BDRX $OCEA $NLSP $AXSM $SERA
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/pl...
$PLRX $BDRX $OCEA $NLSP $AXSM $SERA
February 10, 2025 at 9:29 PM
$PLRX paused enrollment and dosing in its Phase 2b BEACON-IPF trial of bexotegrast for idiopathic pulmonary fibrosis following a review by the independent Data Safety Monitoring Board.
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/pl...
$PLRX $BDRX $OCEA $NLSP $AXSM $SERA
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/pl...
$PLRX $BDRX $OCEA $NLSP $AXSM $SERA
これ、冬のロッククライミングの動画です。視聴回数は少ないけれど、すごいなぁ。極めて危険な箇所でも恐怖を感じず、むしろ、その困難を味わい、楽しんでいる。同じことはできないけれど、自分も自分の実力のうちで、困難を味わい、楽しみたいと思います。
参考：
www.youtube.com/watch?v=plRx...
参考：
www.youtube.com/watch?v=plRx...
【上高地】知られざる冬の姿 ~岩壁をめぐる６日間~. Winter Kamikochi.
YouTube video by 山菜採りオンライン
www.youtube.com
February 28, 2026 at 4:16 PM
これ、冬のロッククライミングの動画です。視聴回数は少ないけれど、すごいなぁ。極めて危険な箇所でも恐怖を感じず、むしろ、その困難を味わい、楽しんでいる。同じことはできないけれど、自分も自分の実力のうちで、困難を味わい、楽しみたいと思います。
参考：
www.youtube.com/watch?v=plRx...
参考：
www.youtube.com/watch?v=plRx...
@presentcorrect.bsky.social, she mentions you. I'll let you guess where... 😉
www.youtube.com/watch?v=PlrX...
www.youtube.com/watch?v=PlrX...
Getting Better At Saying No | Sarah Millican
YouTube video by Sarah Millican
www.youtube.com
September 1, 2025 at 3:54 AM
@presentcorrect.bsky.social, she mentions you. I'll let you guess where... 😉
www.youtube.com/watch?v=PlrX...
www.youtube.com/watch?v=PlrX...
Pliant Therapeutics pauses enrollment and dosing in a mid-stage study of its lung fibrosis candidate following safety board recommendation. $PLRX was down 58% premarket Monday.
endpts.com/pliant-share...
endpts.com/pliant-share...
Pliant pauses Phase 2b lung fibrosis study after safety board recommendation, shares plummet
Pliant Therapeutics pauses enrollment in Phase 2b BEACON-IPF trial of bexotegrast following DSMB recommendation, with unclear reasons for the halt.
endpts.com
February 10, 2025 at 2:40 PM
Pliant Therapeutics pauses enrollment and dosing in a mid-stage study of its lung fibrosis candidate following safety board recommendation. $PLRX was down 58% premarket Monday.
endpts.com/pliant-share...
endpts.com/pliant-share...
hey I've toyed around with jellyfin a few months ago but haven't picked it back up since. should I go ahead and stick with that or see what plrx has going for it before this (unreasonably high) price hike?
new Lifetime Plex Pass will price increase to $749.99 on July 1st (from $249.99) www.plex.tv/blog/new-lif...
May 19, 2026 at 3:43 PM
hey I've toyed around with jellyfin a few months ago but haven't picked it back up since. should I go ahead and stick with that or see what plrx has going for it before this (unreasonably high) price hike?
Most searched small-cap stocks, Mon Feb 10th - #KULR #MBOT #IVVD #QBTS #EH #BB #LAES #RR #LUNR #WULF #OPK #RXRX #POWL #DOMH #SMR #PLRX #PLYA #BDRX #MNTS #GERN - More: crystalequityresearch.com/SmCpStr/ - #smallcap
SmCpStr Technicals – Technical Indicators for Small-cap Stocks
crystalequityresearch.com
February 10, 2025 at 10:36 PM
#BiotechHangout: Daphne Zohar, Eric Schmidt, Tess Cameron, Brian Skorney, Yaron Werber on market/investor blues, #TDCowen Conf, deals ($JAZZ + $CMRX, $ABBV + $GUBRA,Merck KgaA + $SWTX), data ($PLRX, $BHVN, $BMY), RFK Jr's #measles response, Senate hearings,$PFE Cavazzoni appt: x.com/i/spaces/1rm...
March 7, 2025 at 4:53 PM
#BiotechHangout: Daphne Zohar, Eric Schmidt, Tess Cameron, Brian Skorney, Yaron Werber on market/investor blues, #TDCowen Conf, deals ($JAZZ + $CMRX, $ABBV + $GUBRA,Merck KgaA + $SWTX), data ($PLRX, $BHVN, $BMY), RFK Jr's #measles response, Senate hearings,$PFE Cavazzoni appt: x.com/i/spaces/1rm...
We are rebuilding all former blue and gold GP38s into GP20ECOs, all units will be shipped off to PLRX on November 1st. any and all foamers caught trying to catch these units before they leave will be shot by our wonderful conductor on 323.
October 27, 2024 at 2:56 AM
We are rebuilding all former blue and gold GP38s into GP20ECOs, all units will be shipped off to PLRX on November 1st. any and all foamers caught trying to catch these units before they leave will be shot by our wonderful conductor on 323.
BUY $PLRX (PLRX.O) [FDA] @ 12:30:01Z
August 18, 2026 at 12:30 PM
BUY $PLRX (PLRX.O) [FDA] @ 12:30:01Z
#$PLRX receives FDA Fast Track for oral PLN-101095 + Keytruda in ICI-refractory solid tumors. Cash runway into 2H 2028; data expected 2027. notreload.xyz/xy/plrx-gets...
Pliant Gets FDA Fast Track for PLN-101095 in Solid Tumors
PLRX receives FDA Fast Track for oral PLN-101095 + Keytruda in ICI-refractory solid tumors. Cash runway into 2H 2028; data expected 2027.
notreload.xyz
August 18, 2026 at 3:10 PM
#$PLRX receives FDA Fast Track for oral PLN-101095 + Keytruda in ICI-refractory solid tumors. Cash runway into 2H 2028; data expected 2027. notreload.xyz/xy/plrx-gets...
#PLRX Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
https://www.stocktitan.net/news/PLRX/pliant-therapeutics-receives-fda-fast-track-designation-for-pln-y80o1etn2qga.html
https://www.stocktitan.net/news/PLRX/pliant-therapeutics-receives-fda-fast-track-designation-for-pln-y80o1etn2qga.html
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
Pliant Therapeutics (Nasdaq: PLRX) reported that the U.S. FDA has granted Fast Track designation to PLN-101095, an oral dual selective inhibitor of αvβ8 and αvβ1 integrins, in combination with pembrolizumab for the potential treatment of solid tumors resistant to immune checkpoint inhibitors (ICIs).PLN-101095 is being studied in the Phase 1a/1b FORTIFY trial (NCT06270706), with data expected in 2027. According to Pliant Therapeutics, Fast Track status may allow more frequent FDA interactions, rolling New Drug Application submissions and eligibility for priority review if criteria are met.
www.stocktitan.net
August 18, 2026 at 12:30 PM
#PLRX Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
https://www.stocktitan.net/news/PLRX/pliant-therapeutics-receives-fda-fast-track-designation-for-pln-y80o1etn2qga.html
https://www.stocktitan.net/news/PLRX/pliant-therapeutics-receives-fda-fast-track-designation-for-pln-y80o1etn2qga.html
Pliant Therapeutics (NASDAQ:PLRX) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) released its earnings results on Tuesday. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.01),…
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) released its earnings results on Tuesday. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.01),…
Pliant Therapeutics (NASDAQ:PLRX) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) released its earnings results on Tuesday. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.01), FiscalAI reports. Pliant Therapeutics Stock Performance PLRX stock opened at $1.03 on Wednesday. The company’s fifty day moving average price is $1.12 and its 200-day moving [...]
news-area.com
August 12, 2026 at 11:28 PM
Pliant Therapeutics (NASDAQ:PLRX) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) released its earnings results on Tuesday. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.01),…
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) released its earnings results on Tuesday. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.01),…
#PLRX Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
https://www.stocktitan.net/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-second-my2rznktplc6.html
https://www.stocktitan.net/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-second-my2rznktplc6.html
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Pliant
www.stocktitan.net
August 11, 2026 at 8:05 PM
#PLRX Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
https://www.stocktitan.net/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-second-my2rznktplc6.html
https://www.stocktitan.net/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-second-my2rznktplc6.html
🚨 $PLRX
On August 11, 2026, Pliant Therapeutics, Inc. issued a press release announcing the Company’s financial results for the second quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 to this report.
On August 11, 2026, Pliant Therapeutics, Inc. issued a press release announcing the Company’s financial results for the second quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 to this report.
SEC Filing: PLRX
Click to view the official SEC document.
www.sec.gov
August 11, 2026 at 8:24 PM
🚨 $PLRX
On August 11, 2026, Pliant Therapeutics, Inc. issued a press release announcing the Company’s financial results for the second quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 to this report.
On August 11, 2026, Pliant Therapeutics, Inc. issued a press release announcing the Company’s financial results for the second quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 to this report.